Tweets from Hootsuite

Brooke Howitt (Briham and Womens) "Association of POLE-mutated and MSI endometrial ca w/ higher expression of PD-L1" #ASCO15

4:38pm June 1st 2015 via Hootsuite

Daud: Median time to response was 8w. Duration PD-1 > PD-L-1. Both active in pts heavily pretreated for ovarian ca #ASCO15

4:30pm June 1st 2015 via Hootsuite

Daud: PD-1 vs PD-L-1 are both active. #ASCO15 '15 Nature Rev Immunol '15 http://t.co/ZDLXv2Cw8Z Varga results: mild AE's ORR 11%

4:29pm June 1st 2015 via Hootsuite

Daud:Shows somatic mutation plot from Alexandrov Nature '13 paper http://t.co/o2As7p6CnH Mut burden of ovarian in middle #ASCO15

4:25pm June 1st 2015 via Hootsuite

Adil Daud (UCSF) "Paddling Along with PD-L1 Research" #ASCO15

4:23pm June 1st 2015 via Hootsuite

Varga: One example of reduction shown; pt already had 4 treatments, dramatic results. Review: no mortality, no discont. b/c of AE #ASCO15

4:22pm June 1st 2015 via Hootsuite

Varga: 11.5% ORR, 1pt w/compl. resp, 2 partial. 6 stable disease (total 34%, cohort heavily pre-treated). Waterfall: 23% decreased #ASCO15

4:21pm June 1st 2015 via Hootsuite

Varga: IHC using 22C3 Merck Ab. N=26; age 57y; all rec'd carboplatin. 69% had AE, Only 1 grade 3 AE (3.8%), no grade 4-5. #ASCO15

4:19pm June 1st 2015 via Hootsuite

Varga: Ov ca:12K new cases in US. 93% tumors have PD-1+ TILs. Phase 1b study: pembrolizumab Rx 24 mo. ORR primary end-pt. #ASCO15

4:17pm June 1st 2015 via Hootsuite

Andrea Varga (Gustave Roussy) Antitumor activity and safety of pembrolizumab in patients w/ PD-L1+ advanced ovarian cancer #ASCO15

4:14pm June 1st 2015 via Hootsuite

Bernstam: Incidental likely pathogenic muts were found in 4.3% of pts. Relative freq changes by type of tumor and gene. #ASCO15

11:16am June 1st 2015 via Hootsuite

Bernstam: 23/23 pathogenic muts confirmed by different test, 7/23 have already gone onto genetic counselling #ASCO15

11:16am June 1st 2015 via Hootsuite

Bernstam: Clinical recognition of germline pathogenic muts- BRCA1 almost all; BRCA2 only 50%. Others none. Showed #'s why not tested #ASCO15

11:15am June 1st 2015 via Hootsuite

Bernstam: ID'd likely pathogenic germline mutations: br, colon, brain, melanoma. BRCA, PTEN, TP53 (19 genes) #ASCO15

11:12am June 1st 2015 via Hootsuite

Bernstam: NCT01772771 protocol - somatic mut in archival samples. WES, RNA-Seq as rsrch smples. First 1K pts distribution shown #ASCO15

11:11am June 1st 2015 via Hootsuite

Funda Meric-Bernstam (MD Anderson) "Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients" #ASCO15

11:08am June 1st 2015 via Hootsuite

McWilliams: No change to practice, but there are up- and downsides; providers ordering tests need to be aware. Expense & pt impact #ASCO

11:08am June 1st 2015 via Hootsuite

McWilliams: 65% FP when sequencing tumor-only. Jones '15 ref http://t.co/DWI8nbO1DA Useful for high-level discussion w/germline #ASCO15

11:06am June 1st 2015 via Hootsuite

McWilliams:Even with anti-cancer Rx focus, there will be germline findings. 'We know pts have variable desires to know results' #ASCO15

11:00am June 1st 2015 via Hootsuite

Robert McWilliams (Mayo) "Interpreting Germ-Line and Somatic Mutations Together in Tumor Sequencing" Same MSKCC 1570 cases #ASCO15

10:59am June 1st 2015 via Hootsuite

Schrader: VUS a 'significant burden' downstream due to re-analysis. "Most labs need to be prepared to devote significant resources" #ASCO15

10:57am June 1st 2015 via Hootsuite

Kasmintan Schrader (MSKCC) "Tumor relevant germline findings in targeted tumor seq.: matched normal DNA of 1,570 unselected cases" #ASCO15

10:57am June 1st 2015 via Hootsuite

Garon: Some pts will decline second biopsy. T790M plasma testing is viable alternative. May come to clinic fairly soon. #ASCO15

9:43am June 1st 2015 via Hootsuite

Edward Garon (UCLA) Highlights: Non-Small Cell Metastatic Lung Cancer. EGFRi (1/2 in NEJM) http://t.co/cFAWkdZi20 Repeat biopsy #ASCO15

9:42am June 1st 2015 via Hootsuite

Polite: Coord. of care: lay navigation works, saves money, but not needed for everyone (need to target). But savings costs revenue.. #ASCO15

9:39am June 1st 2015 via Hootsuite

Polite: 'This will be the poster child' - will behavior change based on drug cost? Will the costs go down because of this? #ASCO15

9:38am June 1st 2015 via Hootsuite

Polite: Analysis of GALGB/SWOG 80405: no difference betw. Bev & Cetux. Total cost: $40K less for Bevacizumab. #ASCO15

9:36am June 1st 2015 via Hootsuite

Polite:Practices are being held accountable for drug costs - now becoming a potential cost instead of revenue source. #ASCO15

9:35am June 1st 2015 via Hootsuite

Polite: Likely overused services - range from 6% to 41%. Looked at indiv likelihood of consistently choosing - 4x to 18x more likely #ASCO15

9:29am June 1st 2015 via Hootsuite

Polite:MACRA ('doc-fix') consolidates pay-per-performance, and new payment model. Metrics: MSKCC looked Dr variation in oncology #ASCO15

9:27am June 1st 2015 via Hootsuite

Blase Polite (Univ Chicago) Health services rsrch: bridgning gap from volume-based to value. Quality, coord of care, & drug cost #ASCO15

9:23am June 1st 2015 via Hootsuite

Dreicer: Defining molecular subclass of treatment-related prostate ca:defining NEPC by epigenetic changes #ASCO15

9:16am June 1st 2015 via Hootsuite

Dreicer: STAMPEDE: docetaxel and/or zoledronic acid for hormone-naive prostate ca.10mo increase in survival. +zoledronic no improvmt #ASCO15

9:13am June 1st 2015 via Hootsuite

Robert Dreicer (U Virginia) Highlights #ASCO15 prostate ca: ADT intervention TROG trial v small #'s, not benign, known issues (osteoporesis)

9:08am June 1st 2015 via Hootsuite

O'Reilly: Non-CRC GI cancers: few practice changes . End of MET Ab targeting in EG cancers. #ASCO15

9:03am June 1st 2015 via Hootsuite

Eileen O'Reilly (MSKCC) Highlighting panc ca: PIII CONKO-005 trial, Gemcitabine +/- Erlotinib: not meaningful, no DFS OS improvmnt #ASCO15

9:02am June 1st 2015 via Hootsuite

RT @rahman_nazneen: Last cigarette: Beijing brings in smoking bans from Monday. A great decision. http://t.co/6e7JkfntjU

8:50am June 1st 2015 via Hootsuite

The strange connection between Cristiano Ronaldo and a remote dengue fever outbreak - Quartz http://t.co/lNTVIaLNOX

7:20am June 1st 2015 via Hootsuite

RT @oh_henry: Looks like we're at the peak of the hype curve re. #cancer #immunotherapy. Here's some balance: http://t.co/jXgnBcTsLk #ASCO15

6:45am June 1st 2015 via Hootsuite

RT @CompBiolPapers: Rapid draft sequencing and real-time nanopore sequencing in a hospital outbreak of Salmonella. http://t.co/CJC43FHK0C

8:05pm May 31st 2015 via Hootsuite

RT @mbeisen: the comment from Eric Lander on @lpachter's blog is horrifying https://t.co/w8p89Z03Pw

7:05pm May 31st 2015 via Hootsuite

Bryce: Genomics Enabled Medicine for Melanoma (GEMM) Trial - 100 pts, 20 different treatment arms. Huge list (40?) of therapies #ASCO15

6:36pm May 31st 2015 via Hootsuite

Bryce: Looked at germline, transcriptome ID alelle-spec expression. Also ID novel fusion in FGFR, all with intact kinase domains #ASCO15

6:32pm May 31st 2015 via Hootsuite

Bryce: 'Pathologists are our best friend': tissue tested hypothesis. '14 PLOS Gen ref http://t.co/3TVlsZ4bLK Clear, marked response #ASCO15

6:31pm May 31st 2015 via Hootsuite

Bryce: Shows IGV in ERFI1 - impacts EGFR, not thought of as oncogenic. Tumor DNA 11% of reads mutant. Showed up in RNA-Seq 80% ASE #ASCO15

6:30pm May 31st 2015 via Hootsuite

Bryce: Shows circos plot - can use it to bring treatment to pts? Integrating all this information, difficult to do, collab w/TGEN #ASCO15

6:28pm May 31st 2015 via Hootsuite